LOX and type 2 diabetes mellitus: It is suggested that corilagin should be prioritized in further studies on new therapeutics which target the treatment of T2DM and/or asthma because of its dual inhibitory activity against AGLUC and LOX, as well as its several beneficial pharmacological activities and low reported toxicity.